An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer

Arturo Araujo, Leah M Cook, Conor C. Lynch, David Basanta

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Bone metastasis will impact most men with advanced prostate cancer. The vicious cycle of bone degradation and formation driven by metastatic prostate cells in bone yields factors that drive cancer growth. Mechanistic insights into this vicious cycle have suggested new therapeutic opportunities, but complex temporal and cellular interactions in the bone microenvironment make drug development challenging.Wehave integrated biologic and computational approaches to generate a hybrid cellular automata model of normal bone matrix homeostasis and the prostate cancer-bone microenvironment. The model accurately reproduces the basic multicellular unit bone coupling process, such that introduction of a single prostate cancer cell yields a vicious cycle similar in cellular composition and pathophysiology to models of prostate-to-bone metastasis. Notably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal changes in cellular composition. To evaluate the robustness of the model, we assessed the effect of established bisphosphonate and anti-RANKL therapies on bone metastases. At approximately 100% efficacy, bisphosphonates inhibited cancer progression while, in contrast with clinical observations in humans, anti- RANKL therapy fully eradicated metastases. Reducing anti-RANKL yielded clinically similar results, suggesting that better targeting or dosing could improve patient survival. Our work establishes a computational model that can be tailored for rapid assessment of experimental therapies and delivery of precision medicine to patients with prostate cancer with bone metastases.

Original languageEnglish (US)
Pages (from-to)2391-2401
Number of pages11
JournalCancer Research
Volume74
Issue number9
DOIs
StatePublished - Jan 5 2014

Fingerprint

Prostatic Neoplasms
Bone and Bones
Neoplasm Metastasis
Bone Neoplasms
Diphosphonates
Osteogenesis
Prostate
Precision Medicine
Investigational Therapies
Bone Matrix
Tumor Microenvironment
Mesenchymal Stromal Cells
Neoplasms
Homeostasis
Therapeutics
Survival
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. / Araujo, Arturo; Cook, Leah M; Lynch, Conor C.; Basanta, David.

In: Cancer Research, Vol. 74, No. 9, 05.01.2014, p. 2391-2401.

Research output: Contribution to journalArticle

Araujo, Arturo ; Cook, Leah M ; Lynch, Conor C. ; Basanta, David. / An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. In: Cancer Research. 2014 ; Vol. 74, No. 9. pp. 2391-2401.
@article{4ef01a27e8dc4ff98f497f7780977195,
title = "An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer",
abstract = "Bone metastasis will impact most men with advanced prostate cancer. The vicious cycle of bone degradation and formation driven by metastatic prostate cells in bone yields factors that drive cancer growth. Mechanistic insights into this vicious cycle have suggested new therapeutic opportunities, but complex temporal and cellular interactions in the bone microenvironment make drug development challenging.Wehave integrated biologic and computational approaches to generate a hybrid cellular automata model of normal bone matrix homeostasis and the prostate cancer-bone microenvironment. The model accurately reproduces the basic multicellular unit bone coupling process, such that introduction of a single prostate cancer cell yields a vicious cycle similar in cellular composition and pathophysiology to models of prostate-to-bone metastasis. Notably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal changes in cellular composition. To evaluate the robustness of the model, we assessed the effect of established bisphosphonate and anti-RANKL therapies on bone metastases. At approximately 100{\%} efficacy, bisphosphonates inhibited cancer progression while, in contrast with clinical observations in humans, anti- RANKL therapy fully eradicated metastases. Reducing anti-RANKL yielded clinically similar results, suggesting that better targeting or dosing could improve patient survival. Our work establishes a computational model that can be tailored for rapid assessment of experimental therapies and delivery of precision medicine to patients with prostate cancer with bone metastases.",
author = "Arturo Araujo and Cook, {Leah M} and Lynch, {Conor C.} and David Basanta",
year = "2014",
month = "1",
day = "5",
doi = "10.1158/0008-5472.CAN-13-2652",
language = "English (US)",
volume = "74",
pages = "2391--2401",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer

AU - Araujo, Arturo

AU - Cook, Leah M

AU - Lynch, Conor C.

AU - Basanta, David

PY - 2014/1/5

Y1 - 2014/1/5

N2 - Bone metastasis will impact most men with advanced prostate cancer. The vicious cycle of bone degradation and formation driven by metastatic prostate cells in bone yields factors that drive cancer growth. Mechanistic insights into this vicious cycle have suggested new therapeutic opportunities, but complex temporal and cellular interactions in the bone microenvironment make drug development challenging.Wehave integrated biologic and computational approaches to generate a hybrid cellular automata model of normal bone matrix homeostasis and the prostate cancer-bone microenvironment. The model accurately reproduces the basic multicellular unit bone coupling process, such that introduction of a single prostate cancer cell yields a vicious cycle similar in cellular composition and pathophysiology to models of prostate-to-bone metastasis. Notably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal changes in cellular composition. To evaluate the robustness of the model, we assessed the effect of established bisphosphonate and anti-RANKL therapies on bone metastases. At approximately 100% efficacy, bisphosphonates inhibited cancer progression while, in contrast with clinical observations in humans, anti- RANKL therapy fully eradicated metastases. Reducing anti-RANKL yielded clinically similar results, suggesting that better targeting or dosing could improve patient survival. Our work establishes a computational model that can be tailored for rapid assessment of experimental therapies and delivery of precision medicine to patients with prostate cancer with bone metastases.

AB - Bone metastasis will impact most men with advanced prostate cancer. The vicious cycle of bone degradation and formation driven by metastatic prostate cells in bone yields factors that drive cancer growth. Mechanistic insights into this vicious cycle have suggested new therapeutic opportunities, but complex temporal and cellular interactions in the bone microenvironment make drug development challenging.Wehave integrated biologic and computational approaches to generate a hybrid cellular automata model of normal bone matrix homeostasis and the prostate cancer-bone microenvironment. The model accurately reproduces the basic multicellular unit bone coupling process, such that introduction of a single prostate cancer cell yields a vicious cycle similar in cellular composition and pathophysiology to models of prostate-to-bone metastasis. Notably, the model revealed distinct phases of osteolytic and osteogenic activity, a critical role for mesenchymal stromal cells in osteogenesis, and temporal changes in cellular composition. To evaluate the robustness of the model, we assessed the effect of established bisphosphonate and anti-RANKL therapies on bone metastases. At approximately 100% efficacy, bisphosphonates inhibited cancer progression while, in contrast with clinical observations in humans, anti- RANKL therapy fully eradicated metastases. Reducing anti-RANKL yielded clinically similar results, suggesting that better targeting or dosing could improve patient survival. Our work establishes a computational model that can be tailored for rapid assessment of experimental therapies and delivery of precision medicine to patients with prostate cancer with bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=84900001671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900001671&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-2652

DO - 10.1158/0008-5472.CAN-13-2652

M3 - Article

VL - 74

SP - 2391

EP - 2401

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -